Ananth Sridhar

Ananth Sridhar has extensive work experience in corporate development and advisory roles in the pharmaceutical and biotech industry. Ananth is currently serving as the Senior Vice President of Corporate Development at Eidos Therapeutics, a position they have held since May 2022. Prior to this role, they were the Vice President of Corporate Development at Eidos Therapeutics from January 2021 to May 2022. Before joining Eidos Therapeutics, Ananth was the Senior Director of Corporate Development at the same company from August 2018 to January 2021. Ananth also held similar positions at Calcilytix Therapeutics, where they were the Senior Vice President of Corporate Development since May 2022, and previously, the Vice President of Corporate Development from January 2020 to May 2022. Ananth has also worked as an advisor for VALIS Genomics from 2018 to 2020 and Nanoly Bioscience, Inc. from 2013 to 2020. Prior to their corporate development roles, Ananth gained experience in project management and research, including roles at Regeneron Pharmaceuticals, Inc., Genentech, and Stanford University School of Medicine. Ananth holds a strong background in the biotech and pharmaceutical industries and has deep expertise in corporate development and strategic planning.

Ananth Sridhar's education history includes a Bachelor of Science degree with Honors in Chemical Engineering from Stanford University. Additionally, they have a Master of Business Administration (MBA) from Harvard Business School. The start and end years for both degrees are not provided.